NovaBay Pharmaceuticals, Inc. (NBY) Financial Ratios
20 years of historical data (2005–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 5.20
30Y Low1.3·High113.7
ROE
↓
-453.6%
↑-148% vs avg
5yr avg: -182.6%
30Y Low-454%·High26%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.2·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NBY Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NovaBay Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9M | $10M | $4M | $16M | $82M | $122M | $69M | $66M | $295M | $254M | $338M |
| Enterprise Value | $10M | $11M | $4M | $12M | $75M | $111M | $66M | $63M | $292M | $244M | $337M |
| P/E Ratio → | -0.58 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.90 | 1.05 | 0.41 | 1.09 | 8.05 | 12.31 | 10.49 | 5.27 | 16.18 | 21.32 | 77.14 |
| P/B Ratio | — | — | 1.29 | 1.49 | 8.08 | 9.92 | 71.17 | 13.30 | 113.72 | 35.72 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NBY EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.17 | 0.37 | 0.86 | 7.37 | 11.15 | 10.06 | 5.01 | 16.01 | 20.52 | 76.97 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
NBY Profitability
Margins and return-on-capital ratios measuring operating efficiency
NovaBay Pharmaceuticals, Inc. earns an operating margin of -59.7%. Operating margins have expanded from -100.1% to -59.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -453.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.3% | 66.3% | 58.2% | 54.0% | 63.8% | 60.0% | 73.7% | 88.0% | 84.7% | 79.3% | 71.2% |
| Operating Margin | -59.7% | -59.7% | -39.2% | -100.1% | -86.8% | -64.7% | -142.4% | -62.9% | -40.1% | -92.3% | -479.7% |
| Net Profit Margin | -73.8% | -73.8% | -92.2% | -73.6% | -57.1% | -111.1% | -146.4% | -52.3% | -40.6% | -110.5% | -433.1% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -453.6% | -453.6% | -139.0% | -102.4% | -51.8% | -166.1% | -325.9% | -173.4% | -152.7% | -1313.1% | — |
| ROA | -116.0% | -116.0% | -75.8% | -52.5% | -29.7% | -83.4% | -93.9% | -67.3% | -58.2% | -128.6% | -300.8% |
| ROIC | -217.0% | -217.0% | -60.6% | -206.9% | -325.3% | -554.6% | — | -1012.6% | — | — | — |
| ROCE | -218.9% | -218.9% | -48.6% | -88.2% | -53.8% | -71.6% | -170.2% | -148.3% | -90.5% | -191.0% | -906.6% |
NBY Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $1M ($2M total debt minus $430000 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.83 | 0.19 | 0.05 | 0.04 | 4.16 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.12 | -0.31 | -0.68 | -0.93 | -2.97 | -0.64 | -1.23 | -1.34 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -6.46 | -6.46 | -2.42 | — | — | — | -8.93 | — | — | — | — |
NBY Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.68x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.66x to 0.68x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.68 | 0.68 | 1.67 | 2.66 | 3.83 | 5.03 | 1.65 | 2.24 | 1.81 | 3.35 | 0.98 |
| Quick Ratio | 0.41 | 0.41 | 1.00 | 1.85 | 2.89 | 4.81 | 1.56 | 2.16 | 1.71 | 3.15 | 0.69 |
| Cash Ratio | 0.15 | 0.15 | 0.73 | 1.26 | 2.18 | 4.22 | 1.22 | 0.83 | 0.64 | 2.20 | 0.51 |
| Asset Turnover | — | 2.86 | 1.16 | 0.88 | 0.43 | 0.65 | 0.59 | 1.34 | 1.81 | 0.77 | 0.86 |
| Inventory Turnover | 4.31 | 4.31 | 1.52 | 1.93 | 1.15 | 6.53 | 3.53 | 5.37 | 5.52 | 2.82 | 0.94 |
| Days Sales Outstanding | — | 14.52 | 26.50 | 51.09 | 60.31 | 40.64 | 58.96 | 101.93 | 74.38 | 70.10 | 44.66 |
NBY Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NovaBay Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $3M | $120001 | $46000 | $35629 | $28633 | $17666 | $13925 | $12509 | $12549 | $27314 |
Peer Comparison
Compare NBY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NBYYou | $9M | -0.6 | — | — | 66.3% | -59.7% | -453.6% | -217.0% | — |
 AYTU | $18M | -1.0 | — | — | 69.0% | -11.8% | -58.1% | -33.5% | — |
 PRPH | $369487 | -0.0 | — | — | 31.9% | -415.4% | -271.5% | -62.5% | — |
 OGEN | $3M | -0.1 | — | — | — | — | -243.9% | -417.9% | — |
 CTXR | $6M | -0.2 | — | — | — | — | -49.4% | -39.5% | — |
 PCYO | $270M | 20.7 | 25.6 | 73.2 | 61.4% | 29.4% | 9.6% | 4.7% | 0.7 |
 PAHC | $1B | 26.1 | 12.5 | 30.1 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 DERM | $177M | -13.7 | — | — | 59.3% | -13.2% | -44.0% | -36.8% | — |
 CLX | $11B | 13.9 | 9.8 | 14.4 | 45.0% | 16.6% | 166.3% | 27.7% | 2.1 |
 PG | $345B | 22.7 | 15.9 | 24.6 | 51.2% | 24.3% | 31.1% | 20.1% | 1.5 |
 HSIC | $9B | 24.1 | 11.7 | 15.8 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
NBY — Frequently Asked Questions
Quick answers to the most common questions about buying NBY stock.
What is NovaBay Pharmaceuticals, Inc.'s P/E ratio?
NovaBay Pharmaceuticals, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
What is NovaBay Pharmaceuticals, Inc.'s ROE?
NovaBay Pharmaceuticals, Inc.'s return on equity (ROE) is -453.6%. The historical average is -143.3%.
Is NBY stock overvalued?
Based on historical data, NovaBay Pharmaceuticals, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are NovaBay Pharmaceuticals, Inc.'s profit margins?
NovaBay Pharmaceuticals, Inc. has 66.3% gross margin and -59.7% operating margin.